Effects of the cannabinoid CB1 receptor agonist CP55,940 and antagonist SR141716A on d-amphetamine-induced behaviours in Cebus monkeys

Journal of Psychopharmacology
Morten V MadsenMaibritt B Andersen

Abstract

Several clinical studies have shown that alterations in the cannabinoid system in the brain may be associated with schizophrenia. Although evidence points towards an antipsychotic potential for cannabinoid antagonists, experimental studies have shown inconsistent behavioural effects of cannabinoid ligands within and across species. The aim of the present study was to explore these contradictory findings in a non-human primate model, predictive of antipsychotic efficacy in humans. The effects of the cannabinoid CB1 receptor antagonist SR141716A and the CB1 receptor agonist CP55,940 were explored in an d-amphetamine-based Cebus monkey model of psychosis. The monkeys were sensitive to extrapyramidal side effects (EPS), and the side-effect profiles of the drugs were explored as well. SR141716A (0.1, 0.25, 0.375, 0.5 and 0.75 mg/kg) and CP55,940 (0.0025, 0.005 and 0.01 mg/kg) were administered by subcutaneous injection alone and in combination with d-amphetamine (0.25mg/kg). SR141716A (0.1-0.5mg/kg) reduced d-amphetamine-induced arousal, while CP55,940 had no significant effect upon d-amphetamine-induced behaviours. No EPS were observed with either of these compounds. These data suggest that cannabinoid CB1 antagonists such as SR141...Continue Reading

References

Jul 1, 1994·Trends in Pharmacological Sciences·P Seeman, H H Van Tol
Mar 7, 1998·European Journal of Pharmacology·G L GessaM Diana
Jan 14, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·L PeacockJ Gerlach
Apr 16, 1999·Nature Neuroscience·A GiuffridaD Piomelli
Aug 10, 1999·European Journal of Pharmacology·G TandaG Di Chiara
Sep 29, 1999·Neuroreport·F M LewekeD Piomelli
Jul 8, 2000·Proceedings of the National Academy of Sciences of the United States of America·P Seeman, S Kapur
Feb 13, 2001·Pharmacology, Biochemistry, and Behavior·J P MeschlerA C Howlett
Jun 1, 2001·Progress in Neuro-psychopharmacology & Biological Psychiatry·M Glass
Jul 13, 2001·Pharmacology & Therapeutics·A C Porter, C C Felder
Jul 28, 2001·CNS Drug Reviews·A Ottani, D Giuliani
Feb 2, 2002·Psychopharmacology·Miquel MartinOlga Valverde
Feb 21, 2002·Progress in Neuro-psychopharmacology & Biological Psychiatry·Alessandra OttaniDaniela Giuliani
May 31, 2002·Pharmacological Reviews·A C HowlettR G Pertwee
Oct 31, 2002·Psychopharmacology·Renee S MartinDavid A Lowe
Feb 1, 2003·Brain Research·Sachin Patel, Cecilia J Hillard
Apr 18, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Maibritt B AndersenThomas Werge
Sep 13, 2003·Lipids in Health and Disease·Nicola De MarchiVincenzo Di Marzo
Oct 29, 2003·The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry·Anissa Abi-Dargham, Holly Moore
Nov 25, 2003·The Annals of Pharmacotherapy·Leslie L Citrome, Ari B Jaffe
Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Shitij Kapur, David Mamo
Jan 31, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Katerina ZavitsanouXu Feng Huang
Feb 18, 2004·Current Medicinal Chemistry·Alessandro SerrettiDomenico Berardi
Mar 17, 2004·Current Opinion in Pharmacology·Herbert Y Meltzer
Jun 1, 2004·The American Journal of Psychiatry·Herbert Y MeltzerUNKNOWN Meta-Trial Study Group

❮ Previous
Next ❯

Citations

Nov 6, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Andrea M DlugosHarriet de Wit
Nov 21, 2007·Clinical Practice and Epidemiology in Mental Health : CP & EMH·Gino Serra, Walter Fratta
Sep 16, 2008·The International Journal of Neuropsychopharmacology·Daniela ViganoDaniela Parolaro
Jul 2, 2008·Expert Review of Neurotherapeutics·Kirsten R Müller-Vahl, Hinderk M Emrich
Mar 12, 2010·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Patrik RoserWolfram Kawohl

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.